Compare Quest Diagnostics Inc (DGX) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Paycom Software Inc — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Paycom Software Inc trades at $146.26 (market cap $6.70B). The key difference: Quest Diagnostics Inc is far larger — about 3.4× Paycom Software Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | PAYC | |
|---|---|---|
Market Cap | $22.80B | $6.70B |
Sector | Health | Technology |
52-Week High | $216.02 | $238.80 |
52-Week Low | $166.45 | $113.59 |
Enterprise Value | $28.82B | $7.31B |
Dividend Yield | 1.67% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Paycom Software (PAYC) trades at $146.50, up 5.34% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 22.44% net income margin and 37.15% ROE, though Q2 2026 earnings are pending. Recent news highlights product innovation with the launch of Asset Management tool and board appointments, supporting growth prospects in the HCM software sector.
Outlook remains positive with analyst consensus price target of $151 suggesting modest upside, balanced by high valuation multiples and competitive pressures. Key risks include execution challenges in maintaining growth momentum and sensitivity to economic cycles affecting HR software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
